Semaglutide (Ozempic, Wegovy).

Semaglutide was approved for type 2 diabetes in 2017 under the brand Ozempic. The weight-management label — Wegovy — followed in 2021, after trials showed sustained weight reduction in non-diabetic patients with obesity or weight-related comorbidities.

The molecule is the same. The administration is the same. The mechanism is the same. What's different is the FDA-approved indication, the maximum labeled dose (Wegovy goes higher), and the insurance landscape — type 2 diabetes coverage is generally broader than weight-management coverage.

We name the distinction because patients sometimes arrive having heard one brand and assuming it's a different drug. It isn't. The honest framing is: this is semaglutide, and the brand name on the box reflects how the FDA has approved its use, not the chemistry. The label split carries practical consequences for dose and coverage — the Wegovy vs Ozempic guide walks them brand by brand.

Patients who do well during titration tend to prioritize protein first at every meal — eggs, yogurt, cottage cheese, fish, chicken — because satiety arrives faster than it used to, and what gets eaten first is what gets eaten. Falling short on protein during rapid weight reduction is a common cause of muscle loss and fatigue.

High-fat meals delay gastric emptying further, which can stack on top of the medication's effect and produce uncomfortable fullness or reflux. We aren't anti-fat — we're saying that a high-fat meal at the wrong moment of the titration is a recipe for a bad afternoon.

Alcohol tolerance often drops. The medication slows gastric emptying, alcohol absorbs differently, and the next-day effect can be more pronounced than expected. We tell patients this in advance, not as a warning, but as information.

Semaglutide (Ozempic, Wegovy) in Los Angeles typically ranges from $300 to $1,000 per month, depending on dose, formulation source, and whether insurance coverage applies. Cash-pay programs at LA medical spas commonly land $400 to $800 per month at therapeutic doses. Compounded semaglutide programs run lower, $300 to $500 per month, though sourcing and clinical oversight vary significantly.

Dose is the primary cost driver. Patients on starting doses (0.25 mg, 0.5 mg) use less medication per month than patients on maintenance doses (1.0 mg, 1.7 mg, 2.4 mg). Most cash-pay programs price by month at the labeled dose, with the per-month figure stepping up as the dose ladder climbs. Total monthly cost can roughly double between the starter and maintenance phases.

Source — branded versus compounded — moves the price most significantly. Branded Ozempic and Wegovy are FDA-approved finished products, with manufacturer pricing and pharmacy markup. Compounded semaglutide is prepared by a 503A or 503B compounding pharmacy, available at lower price points but with sourcing, sterility, and labeling differences worth understanding. We won't recommend compounded semaglutide without disclosing the tradeoffs.

Insurance coverage changes everything. Patients with type 2 diabetes coverage for Ozempic often pay $25 to $50 per month with copay assistance. Patients on Wegovy with weight-management coverage similarly benefit when their plan covers GLP-1s. Patients without coverage pay full cash price. Plan-by-plan variability is significant and worth checking before committing to a program.

Clinic markup and program structure account for the remaining spread. Programs that include monthly visits, dose-titration management, side-effect support, and labs typically price higher than mail-order or remote-only models. The premium reflects the clinical oversight, which matters more than patients sometimes assume during titration.

Tirzepatide (Mounjaro, Zepbound) is the closest adjacent option and the most relevant cost comparison. LA cash-pay tirzepatide programs typically run $350 to $1,200 per month — modestly above semaglutide at comparable doses. Trial data show tirzepatide producing roughly 50 percent greater average weight reduction than semaglutide head-to-head. For patients evaluating cost-per-result, tirzepatide's higher monthly cost often delivers more weight change per dollar.

Older oral medications — phentermine, naltrexone-bupropion, orlistat — cost $20 to $150 per month and remain reasonable choices for some patients. Average weight reduction is meaningfully less than GLP-1 therapy. For patients with mild weight goals or contraindications to GLP-1s, the older options retain a place in the cost-effectiveness landscape.

Bariatric surgery is the major surgical alternative at $15,000 to $25,000 for sleeve gastrectomy or gastric bypass. For patients with significant obesity and metabolic disease, surgery may be both more effective and more cost-effective long-term than years of GLP-1 medication. The right tool depends on starting BMI, comorbidities, and goals.

For patients on semaglutide who plateau, switching to tirzepatide is a common next step. The cost increase per month is modest; the response often justifies it. Switching back the other direction (from tirzepatide to semaglutide) is rarer and usually driven by tolerability rather than cost.

Pricing at Swissa Med Spa is determined at consultation, where we evaluate candidacy, labs, and discuss source options. The monthly program cost is shared in writing before initiation, with dose escalations and program adjustments handled at scheduled visits — not as billable surprises.